Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tranzyme Pharma has announced that the United States Adopted Name Council (USAN) has approved the generic name, 'Ulimorelin' for the company's new, late-stage, prokinetic agent TZP-101.
Subscribe to our email newsletter
Ulimorelin, if approved, is expected to be a first-in-class drug for the treatment of gastrointestinal (GI) dysmotility indications in acute care settings. Ulimorelin is a small molecule, intravenously-administered drug that targets the ghrelin receptor.
The company said that the safety and pharmacokinetic profiles of Ulimorelin have been extensively characterized in healthy subjects and patients across multiple dose levels, and the GI prokinetic properties of the compound have been well established in humans.
To date, Ulimorelin has been successfully studied in two international phase 2 trials, one for the management of postoperative ileus (POI) and the second for the treatment of acute gastroparesis. It has the potential to treat other conditions where a safe and effective GI prokinetic therapy is desired in acute care settings, claims Tranzyme.